Research
Hormonal
Tirzepatide (15 mg once weekly) combined with lifestyle counseling produces a mean weight loss of 20.9% over 72 weeks in patients with obesity or overweight.
If you are prescribed Tirzepatide (Zepbound), expect to take a 15 mg injection once weekly. This works best when combined with a 500 kcal daily caloric deficit, physical activity, and lifestyle counseling. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.
GoodSupportsHIGH confidence
At 72 weeks, the mean weight loss was 20.9% in the 15 mg group... in the SURMOUNT-1 trial, patients were randomized to receive either 15 mg, 10 mg, 5 mg or placebo combined with lifestyle counseling, physical activity, and diet with a caloric deficit of 500 kcal per day.
Why this rating
Based on a phase II randomized controlled trial (SURMOUNT-1).
Source
Medical Management of Obesity: Current Trends and Future Perspectives
Andrés Calderón et al. · Methodist DeBakey Cardiovascular Journal · 2025
DOI 10.14797/mdcvj.1503
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (2.4 mg once weekly) produces a mean weight loss of 14.9% over 68 weeks in patients with obesity without diabetes.Good
- Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.Good
- GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →